Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
(EGT) stock logo
EGT
(EGT)
$2.34
$0.00
$1.20
$3.25
N/AN/A21,846 shsN/A
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
$3.43
-2.0%
$2.79
$1.87
$11.40
$299.57M-0.161.52 million shs502,550 shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
(EGT) stock logo
EGT
(EGT)
0.00%0.00%0.00%0.00%0.00%
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
+6.40%+15.95%-0.29%-3.86%-41.93%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
(EGT) stock logo
EGT
(EGT)
N/AN/AN/AN/AN/AN/AN/AN/A
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
3.9272 of 5 stars
3.31.00.04.13.02.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
(EGT) stock logo
EGT
(EGT)
0.00
N/AN/AN/A
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
2.60
Moderate Buy$15.63355.54% Upside

Current Analyst Ratings Breakdown

Latest ALGW, HOYE, TERN, and EGT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/13/2025
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$26.00 ➝ $15.00
4/21/2025
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$20.00 ➝ $20.00
3/21/2025
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform
(Data available from 6/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
(EGT) stock logo
EGT
(EGT)
N/AN/AN/AN/AN/AN/A
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
N/AN/AN/AN/A$4.13 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
(EGT) stock logo
EGT
(EGT)
N/AN/A0.00N/AN/AN/AN/AN/A
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
-$90.21M-$1.09N/AN/AN/AN/A-32.76%-31.33%8/4/2025 (Estimated)

Latest ALGW, HOYE, TERN, and EGT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
-$0.29-$0.26+$0.03-$0.26N/AN/A
3/20/2025Q4 2024
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
-$0.30-$0.24+$0.06-$0.24N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
(EGT) stock logo
EGT
(EGT)
N/AN/AN/AN/AN/A
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
(EGT) stock logo
EGT
(EGT)
N/AN/AN/A
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
N/A
32.99
32.99

Institutional Ownership

CompanyInstitutional Ownership
(EGT) stock logo
EGT
(EGT)
1.57%
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
98.26%

Insider Ownership

CompanyInsider Ownership
(EGT) stock logo
EGT
(EGT)
4.70%
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
1.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
(EGT) stock logo
EGT
(EGT)
N/AN/AN/ANot Optionable
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
4087.34 million72.11 millionNot Optionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
(EGT) stock logo

(EGT) NASDAQ:EGT

Entertainment Gaming Asia Inc. is a gaming company. The Company is engaged in slot operations, which include the ownership and leasing of electronic gaming machines (EGMs) in resorts, hotels and other venues; the design, manufacture and distribution of gaming chips and plaques, and the development of a social casino gaming platform designed for the Pan-Asian market. The Company conducts business in two operating segments: gaming operations, which includes slot participation operations, and gaming products, which consists of the design, manufacture and distribution of gaming chips and plaques. Its gaming operations consist of slot operations in Cambodia and the Philippines. Its gaming products consist of the manufacture and sale of gaming chips and plaques under its Dolphin brand and the distribution of gaming products in select markets for third-party suppliers. It identifies and develops new gaming venues, acquires EGMs, casino management systems and other gaming peripherals.

Terns Pharmaceuticals stock logo

Terns Pharmaceuticals NASDAQ:TERN

$3.43 -0.07 (-2.00%)
As of 01:15 PM Eastern

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.